What's new

Part of ARPANSA’s role is the regulation of all Commonwealth entities that use radiation. Regulation ensures compliance with the Australian Radiation Protection and Nuclear Safety Act 1998 and associated Regulations (2018) and is supported by a series of regulatory guides.

In December 2018, the British Medical Journal Open published a scientific study led by ARPANSA investigating the relationship between brain cancer and mobile phone use. Since the publication of the original study, the authors have conducted further analysis of additional age groups.

We’re pleased to announce that the newest location in our ultraviolet (UV) radiation monitoring network is now online. Emerald is the fourth location in Queensland to join our network of real-time UV data.

ARPANSA collates and publishes an annual report on radiation incidents in Australia. This report is produced with input from various radiation regulators around the country, based on incidents submitted to them and any subsequent investigations they carry out.

In Australia, skin cancer accounts for around 80% of all newly diagnosed cancers each year and UV radiation from the sun is one of the leading causes of skin cancer. With high UV radiation year-round in many parts of Australia, people who regularly work outside face a higher risk of developing cancer from sun exposure.

Dr Gillian Hirth, deputy CEO and Head of ARPANSA's Radiation Health Services Branch, has been elected as Chair of the United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) for the 66th and 67th sessions

Production of nuclear medicine at ANSTO’s Nuclear Medicine facility was halted on 21 June following an accident in which the hands of three workers were exposed to radiation.

On Friday 21 June 2019, ARPANSA was notified of a radiation contamination event at the Australian Nuclear Science and Technology Organisation (ANSTO) Nuclear Medicine (ANM) production facility in Lucas Heights, New South Wales.

ARPANSA is aware that there is a lot of concerning misinformation circulating throughout the community about the possible impacts of Australia’s planned roll-out of the 5G mobile network.

We have published the Guide for Radiation Protection in Emergency Exposure Situations.

ARPANSA’s CEO, Dr Carl-Magnus Larsson has amended a licence issued to the Australian Nuclear Science and Technology Organisation (ANSTO) to operate the ANSTO Nuclear Medicine (ANM) facility.

​​​​​​​Recently, ARPANSA co-authored a new study which found that modern airline pilots registered in Australia, appear not to be at higher risk of developing invasive melanoma than the rest of the population.

We’re pleased to be partnering with the Central Highlands Regional Council to establish Queensland’s fourth location for collection of real time ultraviolet (UV) data.

ARPANSA has granted the Australian Nuclear Science and Technology Organisation (ANSTO) an amended license to allow for the limited production of molybdenum-99 in order to sustain supply.

At ARPANSA, we set the safety standard sets limits for exposure to radio frequency (RF) electromagnetic energy (EME) that is emitted by mobile phones and other wireless technologies. These limits are set well below levels at which harm to people may occur. The operating frequencies of the 5G network are included within the limits set by the ARPANSA safety standard.

We’re excited to announce that we have installed a new linear accelerator (linac) at ARPANSA, to continue ensuring any Australians undergoing medical procedures receive the correct amount of radiation.

The Governor-General has reappointed Dr Carl-Magnus Larsson as the CEO of ARPANSA for a term of three years.

We’ve released national advice for light-based cosmetic treatments in Australia for both patients and practitioners.